Radiochemotherapy in Pancreatic Cancer

8Citations
Citations of this article
18Readers
Mendeley users who have this article in their library.

Abstract

Despite the advancements made in oncology in recent years, the treatment of pancreatic cancer remains a challenge. Five-year survival rates for this cancer do not exceed 10%. Among the reasons contributing to poor treatment outcomes are the oligosymptomatic course of the tumor, diagnostic difficulties due to the anatomical location of the organ, and the unique biological features of pancreatic cancer. The mainstay of treatment for resectable cancer is surgery and adjuvant chemotherapy. For unresectable and metastatic cancers, chemotherapy remains the primary method of treatment. At the same time, for about thirty years, there have been attempts to improve treatment outcomes by using radiotherapy combined with systemic treatment. Unlike chemotherapy, radiotherapy has no established place in the treatment of pancreatic cancer. This paper addresses the topic of radiotherapy in pancreatic cancer as a valuable method that can improve treatment outcomes alongside chemotherapy.

Cite

CITATION STYLE

APA

Domagała-Haduch, M., Gorzelak-Magiera, A., Michalecki, Ł., & Gisterek-Grocholska, I. (2024, June 1). Radiochemotherapy in Pancreatic Cancer. Current Oncology. Multidisciplinary Digital Publishing Institute (MDPI). https://doi.org/10.3390/curroncol31060250

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free